WHO 3级胶质瘤切除范围决策系统:中国胶质瘤基因组图谱数据库分析
基于中国胶质瘤基因组图谱数据库2006—2020年246例WHO 3级IDH突变型胶质瘤患者资料,分析切除范围按分子病理和临床特征分层对总生存的影响;全切除与星形细胞瘤组更长生存在关联,少突胶质细胞瘤组无此关联,年龄≤45岁星形细胞瘤患者全切除较次全切除生存更长。
要点
- 切除范围是全队列独立预后因素,校正分子病理后仍独立。
- 全切除与更长生存相关见于全部患者和星形细胞瘤组,少突胶质细胞瘤组未见。
- 年龄≤45岁星形细胞瘤患者全切除较次全切除生存更长,>45岁者无生存获益。
核心结论
- 广泛切除仅使部分WHO 3级IDH突变型胶质瘤患者获益。
- 年轻星形细胞瘤患者从广泛切除中获得生存获益。
- 除临床特征(尤其年龄)外,分子病理也影响胶质瘤患者预后。
- 研究结果为神经外科医生规划手术提供指导信息。
研究设计与样本
- 从中国胶质瘤基因组图谱数据库(2006—2020年)收集246例WHO 3级IDH突变型胶质瘤患者的临床与病理信息。
- 按分子病理和临床特征分层,分析切除范围对总生存的作用。
- 在各亚组采用单变量对数秩检验和多变量Cox比例风险模型评估预后因素。
主要发现
- 切除范围是整个队列的独立预后因素,校正分子病理后仍为独立预后因素。
- 全切除与全部患者和星形细胞瘤组的更长生存相关,但与少突胶质细胞瘤组的生存无关。
- 与次全切除相比,全切除使年龄≤45岁星形细胞瘤患者生存时间更长。
- 年龄>45岁星形细胞瘤患者全切除无生存获益。
临床怎么用
- 作者认为研究结果可为神经外科医生规划手术提供指导信息。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Extensive surgical resection has been found to be associated with longer survival in patients with gliomas, but the interactive prognostic value of molecular pathology of the surgical resection is unclear. This study evaluated the impact of molecular pathology and clinical characteristics on the surgical benefit in WHO grade 3 IDH-mutant gliomas. METHODS: Clinical and pathological information of 246 patients with WHO grade 3 IDH-mutant gliomas were collected from the Chinese Glioma Genome Atlas database (2006-2020). The role of the extent of resection on overall survival, stratified by molecular pathology and clinical characteristics, was investigated. We then assessed prognostic factors using a univariate log-rank test and multivariate Cox proportional hazards model in the subgroups. RESULTS: The extent of resection was an independent prognostic factor in the entire cohort, even when adjusted for molecular pathology. Gross total resection was found to be associated with longer survival in all patients and in the astrocytoma group but not in the oligodendroglioma group. Compared with subtotal resections, gross total resections resulted in a longer survival time for astrocytoma patients aged ≤ 45 years. However, there was no survival benefit from total resection in patients with astrocytoma aged > 45 years. CONCLUSIONS: Extensive resection benefits only a proportion of patients with WHO grade 3 IDH-mutant gliomas. Younger patients with astrocytomas had survival benefits from extensive resection. In addition to clinical characteristics (especially age), molecular pathology impacted prognosis in patients with gliomas. Our findings provide guiding information to neurosurgeons while planning surgeries.
引用
- Hou Z, Hu J, Liu X, et al. Decision system for extent of resection in WHO grade 3 gliomas: a Chinese Glioma Genome Atlas database analysis. J Neurooncol. 2023. PMID: 37668945. doi:10.1007/s11060-023-04420-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。